The maker of Ozempic and Wegovy is deploying Anthropic’s Claude models across its R&D and engineering — the latest sign that Big Pharma sees AI as a core tool, not an experiment.
The blood-brain barrier blocks most large-molecule drugs from reaching the brain. Novartis is buying Sironax’s delivery technology to get antibodies, proteins and gene therapies through it.
A first-of-its-kind atlas of tiny, overlooked “microproteins” in the human brain uncovered more than 1,000 unknown players — including one that, when lost, saps the energy of the brain’s immune cells.
Kybella is approved only to melt fat under the chin. The FDA is warning that using it elsewhere on the body — an increasingly popular cosmetic trend — has caused serious adverse reactions.
New evidence suggests that for people with one or two small, low-risk polyps removed, waiting longer between follow-up colonoscopies is safe — sparing patients procedures many are getting too often.
In its final Phase 3 analysis, Trutakna (atacicept) essentially stabilized kidney function and cut disease-progression events by 76% in IgA nephropathy — strong data as Vera pushes for full FDA approval.
Pooling 139 trials, researchers found the most effective drug-free treatments for knee osteoarthritis were surprisingly simple: knee braces, water-based therapy and regular exercise — while a common clinic staple ranked near the bottom.
GSK is paying up to $750 million for global rights to Chimagen’s trispecific T-cell engager for multiple myeloma — the latest sign of the company rebuilding the oncology franchise it sold off a decade ago.
Curium’s Bexlutry, a generic of Novartis’s Lutathera, is the first “radioligand equivalent” approved in the U.S. — a milestone that could open a fast-growing but supply-constrained corner of cancer care to competition.
A detailed look inside the aging hippocampus reveals that brain aging isn’t a slow, steady slide — it’s a coordinated overhaul of the brain’s immune and blood-vessel systems that peaks in a specific midlife-to-later-life window.
Breast cancer patients with vitamin D deficiency needed more pain medicine and reported more moderate pain after mastectomy — a suggestive link, though the study can’t prove cause and effect.
Up to 1 in 5 people with high blood pressure may have a hormone disorder that standard daytime blood tests overlook — because the telltale hormone surges mostly at night.